Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Market Movers
TipRanks 50 Index
Dividend Stocks
AI Stocks
Largest Companies by Market Cap
ETFs
Top ETFs by Upside
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Ideas
Plans
Research Tools
Trending Stocks
Compare Stocks
Compare ETFs
Daily Feeds
Daily Analyst Ratings
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Economic Indicators
Inflation Rate
Unemployment Rate
Class Actions
Tools
Plans
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Screeners
Plans
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Dividends
Plans
My Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Experts
Plans
Portfolio
Plans
Trending News
More News >
News
Plans
Enterprise Solutions
Plans
Education
Personal Finance
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Advertise with Us
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
More
Plans
Plans & Pricing
Plans
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Screeners
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Ideas
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Research Tools
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Calculators
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividends
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Market Movers
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
More
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Log Out
QURE
Stock Latest News
The Fly
Lake Street says AMT-130 could be ‘significantly impactful’ for ClearPoint
8d ago
CLPT
QURE
Premium
Ratings
Positive Outlook for uniQure’s AMT-130 Program Drives Buy Rating Amid Regulatory Advancements and Robust Clinical Framework
8d ago
QURE
Premium
Ratings
Buy Rating for uniQure Driven by Promising AMT-130 Advancements and Strategic FDA Alignment
8d ago
QURE
Premium
The Fly
RBC Capital views FDA flexibility on another HD drug as positive for PTC’s ‘518
8d ago
PTCT
QURE
Premium
Ratings
uniQure’s AMT-130 Gains Momentum with FDA Support and Promising Clinical Outlook
8d ago
QURE
Premium
Company Announcements
uniQure Aligns with FDA for AMT-130 BLA Approval
9d ago
8K
QURE
Premium
The Fly
uniQure provides regulatory update on AMT-130 for Huntington’s Disease
9d ago
QURE
Premium
Ratings
Buy Recommendation for uniQure Driven by Promising AMT-260 Trial Results and Innovative LinQURE Technology
12d ago
QURE
Premium
Ratings
Promising Early Data and Strategic Expansion Bolster Buy Rating for uniQure’s AMT-260 Program
12d ago
QURE
Premium
The Fly
uniQure early AMT-260 data encouraging, says H.C. Wainwright
12d ago
QURE
Premium
The Fly
uniQure presents case study of first patient dosed with AMT-260
13d ago
QURE
Premium
The Fly
Unusually active option classes on open May 21st
20d ago
BTU
TGT
Premium
Ratings
uniQure’s Clinical and Regulatory Progress Drives Buy Rating Amid Market Overreaction
28d ago
QURE
Premium
Ratings
Optimistic Buy Rating on uniQure Amidst Progress in Huntington’s Disease Program and AMT-130 Developments
29d ago
QURE
Premium
Company Announcements
uniQure N.V. Earnings Call: Progress Amid Challenges
29d ago
QURE
Premium
Company Announcements
uniQure Reports Q1 2025 Progress and Financials
1M ago
QURE
Premium
Ratings
Optimistic Outlook on uniQure’s AMT-130 Program Amidst Regulatory Progress and Market Volatility
1M ago
QURE
Premium
Ratings
uniQure’s Promising Developments and Regulatory Progress Drive Buy Rating
1M ago
QURE
Premium
The Fly
Morning Movers: Pinterest, Lyft jump following quarterly results
1M ago
TU
AGM
Premium
The Fly
uniQure reports Q1 EPS (82c), consensus (93c)
1M ago
QURE
Premium
The Fly
uniQure expects cash to fund operations into 2H of 2027
1M ago
QURE
Premium
The Fly
uniQure recent selloff overdone, says H.C. Wainwright
1M ago
QURE
Show More
Trending
Indices
Stocks
ETFs
Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >
You need to enable JavaScript to run this app.
